Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Dec 2019 Trial design presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 14 Jan 2019 Planned primary completion date changed from 1 Mar 2020 to 1 Mar 2021.
- 14 Jan 2019 Planned initiation date changed from 1 Jun 2018 to 1 Jun 2019.